

20030130057

(2)

AD-A203 314

DOCUMENTATION PAGE

FILE

Form Approved  
OMB No. 0704-0182

2a. SECURITY CLASSIFICATION AUTHORITY <b>SECRET</b>		1b. RESTRICTIVE MARKINGS	
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE <b>SECRET</b> JAN 17 1989		3. DISTRIBUTION/AVAILABILITY OF REPORT Distribution unlimited - approved for public release	
4. PERFORMING ORGANIZATION REPORT NUMBER(S) <b>D6</b>		5. MONITORING ORGANIZATION REPORT NUMBER(S)	
6a. NAME OF PERFORMING ORGANIZATION U.S. Army Medical Research Institute of Infectious Diseases		7a. NAME OF MONITORING ORGANIZATION U.S. Army Medical Research and Development Command	
6b. ADDRESS (City, State, and ZIP Code) Fort Detrick, Frederick, MD 21701-5011		7b. ADDRESS (City, State, and ZIP Code) Fort Detrick, Frederick, MD 21701-5012	
8a. NAME OF FUNDING/SPONSORING ORGANIZATION		8b. OFFICE SYMBOL (if applicable)	
8c. ADDRESS (City, State, and ZIP Code)		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER	
10. SOURCE OF FUNDING NUMBERS		11. TITLE (Include Security Classification)	
PROGRAM ELEMENT NO.		PROJECT NO.	
TASK NO.		WORK UNIT ACCESSION NO.	
Effect of Toxins on Arachidonic Acid Metabolism in Cultured Rat Pulmonary Alveolar Macrophages			
12. PERSONAL AUTHOR(S) Syed M. Naseem, Harry B. Hines, and Donald A. Creasia			
13a. TYPE OF REPORT Interim		13b. TIME COVERED FROM _____ TO _____	
14. DATE OF REPORT (Year, Month, Day) 28 December 1988		15. PAGE COUNT 12	
16. SUPPLEMENTARY NOTATION			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	SUB-GROUP	
19. ABSTRACT (Continue on reverse if necessary and identify by block number)		toxin, prostaglandin, metabolism, macrophage, steroid	
The action of a trichothecene (T-2), microcystin-LR and saxitoxin on arachidonic acid metabolism in cultured rat alveolar macrophages was studied. Pulmonary macrophages exposed to 10 <sup>-6</sup> M T-2 were stimulated to synthesize and increase in release thromboxane B <sub>2</sub> (TxB <sub>2</sub> ) by 56% and 6-KetoF <sub>2</sub> α (73%). Microcystin-LR induced a significant increase in release of prostaglandins F <sub>2</sub> α (40%), PGE <sub>2</sub> (75%) and TxB <sub>2</sub> (69%), as compared to controls. Saxitoxin increased TxB <sub>2</sub> release by 37%. Arachidonic acid release was stimulated by all three toxins tested. The release of arachidonic acid and its metabolites by alveolar macrophages exposed to T-2 toxin was partially blocked by fluocinolone (1 μM). These results suggest that macrophages synthesize and release inflammatory mediators in response to toxin exposure, and fluocinolone may protect against T-2 toxicosis. (P. 1)			
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION	
22a. NAME OF RESPONSIBLE INDIVIDUAL		22b. TELEPHONE (Include Area Code)	
		22c. OFFICE SYMBOL	

EFFECT OF TOXINS ON ARACHIDONIC ACID METABOLISM IN CULTURED  
RAT PULMONARY ALVEOLAR MACROPHAGES

Syed M. NASEEM, Harry B. HINES and Donald A. CREASIA

U.S. Army Medical Research Institute of Infectious Diseases,  
Division of Pathophysiology, Fort Detrick, Frederick, Maryland  
21701-5011

---

Summary: The action of a trichothecene (T-2), microcystin-LR and saxitoxin on arachidonic acid metabolism in cultured rat alveolar macrophages was studied. Pulmonary macrophages exposed to 1  $\mu$ M T-2 were stimulated to synthesize and increase in release thromboxane B<sub>2</sub> (TxB<sub>2</sub>) by 56% and 6-KetoF<sub>2</sub> $\alpha$  (73%). Microcystin-LR induced a significant increase in release of prostaglandins F<sub>2</sub> $\alpha$  (40%), PGE<sub>2</sub> (75%) and TxB<sub>2</sub> (69%), as compared to controls. Saxitoxin increased TxB<sub>2</sub> release by 37%. Arachidonic acid release was stimulated by all three toxins tested. The release of arachidonic acid and its metabolites by alveolar macrophages exposed to T-2 toxin was partially blocked by fluocinolone (1  $\mu$ M). These results suggest that macrophages synthesize and release inflammatory mediators in response to toxin exposure, and fluocinolone may protect against T-2 toxicosis.

---

Some natural toxins are potent and powerful inflammatory agents (1,2). For example, dermal administration of T-2 toxin causes skin irritation (3), edema (4,5), and cellular damage (6). Intraruminal injection of *Microcystin aeruginosa* in sheep results in edema of the lung and neutrophil accumulation within the pulmonary arterial tree (7). In these studies the mechanism of irritant action was not determined nor were the inflammatory mediators

---

Address for Correspondence: Dr. Syed M. Naseem, Pathophysiology Division,  
USAMRIID, Fort Detrick, Frederick, MD 21701-5011, Phone: (301) 663-7181

identified, although it is possible that release of inflammatory mediators may be an early step in toxin-induced injury. In a recent study, dexamethasone increased the survival of rats exposed to a lethal dose of T-2 toxin (8). Similarly, hydrocortisone prevented the development of thrombocytopenia in mice treated with microcystin-LR (9). The authors speculated that glucocorticoids inhibit toxicosis by blocking the release of free arachidonic acid through inhibition of phospholipase A<sub>2</sub> activity, and consequently, block the synthesis and the release of both cyclooxygenase and lipoxygenase products (10).

Macrophages are known to release a wide array of inflammatory mediators, such as proteolytic enzymes, chemotactic proteins, and arachidonic acid metabolites (11-13). To study the possible role of macrophages in the inflammatory response to natural toxins, we examined the effect of T-2, microcystin-LR known inflammatory agents, and also included saxitoxin (not yet known to cause inflammatory reactions in any tissues) on arachidonic acid metabolism in rat alveolar macrophages. Alveolar macrophages were selected because they respond immediately to various physiological stimuli by synthesizing and releasing immunoregulatory substances including arachidonic acid cascade (14-15).

## Materials and Methods

### Macrophages

Lungs from 200-280 g Fisher 344 (Charles River, Wilmington, MA) rats were removed and macrophages were isolated by lavage and cultured in 35-mm culture plates (Falcon Labware, Division of Becton-Dickson Co., Oxford, CA) by the procedure described by Grundfest et al. (16). Non-adherent cells were removed by washing the cells twice with Hank's balanced salt solution (HBSS). The adherent cell population contained 95% alveolar macrophages as determined by morphology and biochemical criteria (16).



Administrative Codes	
Date	Approved or Special
A-1	

### *Macrophage Labeling and Stimulation*

After overnight culture, the medium was removed and the cells washed twice with HBSS. [ $^{14}$ C]Arachidonic acid ( $^{14}$ C-AA, sp. act. 52.7 mCi/mmol, New England Nuclear, Boston, MA) in 0.1% lipid-free bovine serum albumin (BSA) in medium 199 was added to the cells. Cultures were then incubated for 60 min at 37°C under 5% CO<sub>2</sub> and 95% air. The cells were washed with HBSS, incubated for another hour with medium 199 containing 10% fetal calf serum (FCS), and then washed three times with HBSS to remove any unincorporated  $^{14}$ C-AA. These  $^{14}$ C-AA-prelabeled macrophages were used to study the release of arachidonic acid and its metabolites. Experiments with T-2 toxin, microcystin-LR and saxitoxin were done in 1 ml HBSS containing 0.1% BSA. The effect of fluocinolone on arachidonic acid metabolite release was determined by stimulating macrophages in the presence or absence of 1  $\mu$ M fluocinolone for 16 hr in culture medium. Cultures were incubated for 2 hr, with final concentrations of toxins as indicated in the Tables. N-ethylmaleimide (NEM, Sigma Chemical Co., St. Louis, Mo), and calcium ionophore A23187 (Calbiochem, Los Angeles, CA) were used as positive controls (16). All experiments were done at least 3 times in duplicate. Cell viability was monitored by trypan blue exclusion and plates were checked by phase contrast microscopy for floating and dead cells.

### *Extraction of Prostaglandins*

After incubation with toxins or other agents, the cultures were placed on ice. The culture medium (HBSS with 0.1% BSA) was removed, the plates were washed with 1 ml HBSS media and washes were pooled and were extracted with chloroform:methanol (1:2 v/v) containing 0.005% butylated-hydroxy toluene (BHT, Sigma Chem. Co., St. Louis, MO) for prostaglandin measurement. In order to partition the extract, additional chloroform and water were added. The final volume of solvents was chloroform:methanol:water (2:2:1.8 v/v). The aqueous phase was washed with 2 ml of chloroform. The chloroform phases were pooled, their total lipid extract evaporated to dryness under nitrogen, and they were stored under nitrogen at -20°C.

### *Determination of Prostaglandins*

Precoated Silica Gel-60 thin layer chromatographic (TLC) plates (E. Merck, American Scientific Products, Columbia, MD) were washed with ethanol and dried overnight at room temperature. The plates were activated at 100°C for 60 min before use. Lipid residue from media was dissolved in 0.1 ml chloroform:methanol (2:1) and quantitatively applied to plates. TLC plates were developed in ethylacetate and formic acid (80:1 v/v) to separate arachidonic acid and its metabolites. Arachidonic acid metabolites produced by alveolar macrophages were identified by comparing the R<sub>f</sub> values to known standards (Sigma Chem. Co., St. Louis, MO). The standards and their corresponding R<sub>f</sub> values were 6 Keto F<sub>2</sub> $\alpha$ , 0.24; PCF<sub>2</sub> $\alpha$ , 0.36; Tx B<sub>2</sub>, 0.57; PGE<sub>2</sub>, 0.63; and arachidonic acid, 0.95. Recovery of these products was always >80% as determined by co-migration of radiolabeled prostaglandin standards. Protein was measured by the Lowry method (17).

### *Scintillation Spectrometry*

Thin-layer chromatograms were exposed to iodine vapor, and lipid spots were identified by their co-migration with their respective standards.

Resolved and identified compounds were scraped, extracted with ethanol for 30 min, and counted for radioactivity in a Beckman scintillation counter. The counting efficiency for  $^{14}\text{C}$  was always >95%.

T-2 toxin [31 $\alpha$ -hydroxy-4 $\beta$ , 15-diacetoxy-8 $\alpha$ -(3-methylbutyryloxy) 12, 13 - epoxy trichothene-9-ene) was purchased from Romer Laboratory, St. Louis, MO. Microcystin-LR and saxitoxin were obtained from Dr. Wayne Carmichael, Wright State University, Dayton, OH, and Dr. Samuel Page, Food and Drug Administration, Washington, D.C., respectively.

**Statistical Analysis.** Statistical significance was evaluated by student "t" test. Relationship between different toxins was estimated by using SAS procedures of one-way analysis of variance with Tukey's method for comparison of means.

## Results

Treatment of alveolar macrophages in culture with T-2, microcystin-LR or saxitoxin for 2 hr resulted in toxin induced release of arachidonic acid metabolites with some toxin specificity (Fig. 1). T-2 toxin treatment of macrophages resulted in significant stimulation of 6-Keto  $\text{F}_{1\alpha}$  production when compared to control, microcystin-LR or saxitoxin exposure ( $p < 0.05$ , one-way analysis of variance). Similar doses of saxitoxin and microcystin-LR showed no effect as compared to control. Microcystin-LR induced a significant release of  $\text{PGF}_{2\alpha}$  and  $\text{PGE}_2$ , but neither T-2 nor saxitoxin affected the release of these compounds. Thromboxane ( $\text{TxB}_2$ ) and arachidonic acid were released by all the toxins, though the magnitude of effect by saxitoxin was less than that of T-2 or microcystin-LR (Fig. 1). The calcium ionophore A23187, stimulated the release of all arachidonic acid metabolites except  $\text{PGF}_{2\alpha}$ , while NEM failed to induce the release of  $\text{PGF}_{2\alpha}$  and 6-Keto  $\text{F}_{1\alpha}$ , (Table 1).

Pretreatment of macrophages with fluocinolone, a potent fluorinated glucocorticoid, completely abolished the stimulatory effect of T-2 on  $\text{TxB}_2$ , and partially reduced the release of 6-Keto  $\text{F}_{1\alpha}$  and free arachidonic acid (Table 2). Other metabolites were not significantly affected by steroid pretreatment in T-2 exposed cultures (data not shown).

## Discussion

Recent studies with inhaled T-2 toxin demonstrate that several trichothecene toxins can reduce the phagocytic activity of pulmonary macrophages (18). Reduction in phagocytic activity could result in suppression of antibody synthesis (19) and pulmonary immune function (18) which suggest an important pathophysiologic role of toxins. We compared the effect of T-2-induced release of cyclooxygenase products with that of saxitoxin and microcystin-LR, as well as with known irritants such as calcium ionophore A23187 and sulfhydryl NEM. Stimulation of T-2, induced release of arachidonic acid metabolites in alveolar macrophages was comparable to microcystin-LR but varies in specificity (Fig. 1). Saxitoxin was least effective in inducing the release of arachidonic acid metabolites, probably due to non-inflammatory nature of the toxin. We observed a large increase in release of  $\text{TxB}_2$  and 6-Keto  $\text{F}_{1\alpha}$  and moderate stimulation of  $\text{PGE}_2$  by T-2 toxin in alveolar macrophages. Shohami et al. (2, 8) reported a similar results of arachidonic acid metabolism by T-2 toxin in regions of the brain.

The inhibition of T-2 toxin-induced arachidonic acid release in fluocinolone-treated macrophages is consistent with the prevailing hypotheses concerning the mechanism by which glucocorticoids inhibit prostaglandin synthesis, contributing to their in-vivo, anti-inflammatory effect (19, 20). Pretreatment of macrophages with steroid significantly augmented the T-2 induced release of  $\text{TxB}_2$  and partially inhibited the release of 6-Keto  $\text{F}_{1\alpha}$  and free arachidonic acid from cellular membrane. This suggests the possibility that fluocinolone may modify arachidonic acid metabolism beyond phospholipase activation by T-2 toxin, and probably also regulate cyclooxygenase synthetic and/or degradative enzymes (22) which has yet to be determined. At any rate,

the data presented here are compatible with other reports (23) that the effects of steroids are not limited to induction of phospholipase A<sub>2</sub> inhibitory protein.

Dunham et al. (24) reported that leukotriene B<sub>4</sub> (LTB<sub>4</sub>) and LTD<sub>4</sub> influence the biosynthesis and release of TxB<sub>2</sub>. Earlier studies indicate that sulfhydryl reagents also stimulate the release of TxB<sub>2</sub> and LTB<sub>4</sub>, but fail to influence PGE<sub>2</sub> and LTC<sub>4</sub> synthesis by inhibiting endoperoxide PGE<sub>2</sub>-isomerase and leukotriene C<sub>4</sub> synthetase, preventing the conversion of arachidonic acid to PGE<sub>2</sub> and LTC<sub>4</sub>, promoting the formation of TxB<sub>2</sub> in alveolar macrophages (16, 25). In this study, another sulfhydryl reagent, NEM, stimulated the release of TxB<sub>2</sub> by 92%. The TxB<sub>2</sub> production by macrophages may be mediated via a sulfhydryl reaction, thus favoring the synthesis of TxB<sub>2</sub>, which is probably controlled by LTB<sub>4</sub> production (26). These results suggest that toxins and sulfhydryl agonists influenced alveolar macrophages in similar fashion to release certain inflammatory materials.

The data from this study together with data from Shahami et al., (8) and Adams et al., (9) suggest that a possible pathogenesis of toxicity of T-2 and microcystin-LR may involve arachidonic acid metabolism.

#### Acknowledgements

We are grateful to Drs. Abram Fajer, William Thompson and Kathy Kenyon (editor) for their helpful advice and valuable discussions and criticisms during the preparation of this manuscript. We especially thank Ms. Jackie Chaco-Farley for typing assistance. The views of the authors do not purport to reflect the position of the Department of the Army or the Department of Defense.

#### References

1. Horowitz, A.D., Fujiki, H., Weinstein, I.B., Jeffrey, A., Okin, E., Moore, R.E., and Sugiyama, T. (1983) *Cancer. Res.* 43, 1529-1535.
2. Shahami, E., and Feuerstein, G. (1986) *Prostaglandins*, 31, 307-319.

3. Ueno, Y., Ishikawa, Y., Amakai, K., Nakajima, M., Saito, M., Enomoto, M., and Ohtsubo, K. (1970) *Jpn. J. Exp. Med.* 40,33-38.
4. Matsuoka, Y., Kubota, K., and Ueno, Y. (1979) *Toxicol. Appl. Pharmacol.* 50,87-94.
5. Feuerstein, G., Goldstein, D.S., Ramwell, P.W., Zerbe, R.L., Lux, W.E., Jr., Faden, A.I., and Bayorh, M.A. (1985) *J Pharmacol Exp Ther* 232,766-794.
6. Saito, M., Enomoto, M., and Tatsuno, T. (1969) *Cancer* 60,599-603.
7. Jackson, A.R., McInnes, A., Falconer, I.R., and Runnegar, M.T. (1984) *Vet. Pathol.* 21,102-113.
8. Shohami, E., Wisotsky, B., Kempinski, O., and Feuerstein, G. (1987) *Pharm. Res.* 4,527-530.
9. Adams, W.H., Stoner, R.D., Adams, D.G., Slatkin, D.N., and Siegelman, H.W. (1985) *Toxicol* 23,441-447.
10. Merker, M.P., and Levine, L. (1986) *Toxicol* 24,451-465.
11. Rouzer, C.A., Scott, W.A., Hamill, A.L., and Cohn, Z.A. (1982) *J. Exp. Med.* 155,720-733.
12. Rankin, J.A., Hitchcock, M., Merrell, W., Bach, M.K., Brasher, J.R., and Askinase, R.W. (1982) *Nature* 293,329-331.
13. Fels, A.O., Pawlowski, N.A., Cramer, E.B., King, T.K., Cohn, Z.A., and Scott, W.A. (1982) *Proc. Natl. Acad. Sci. (U.S.A.)* 79,7866-7870.
14. Goodwin, J.S., and Webb, D.R. (1980) *Clin. Immunol. Immunopathol.* 15,106-122.
15. Hammarstrom, S. (1983) *Ann. Rev. Biochem.* 52,355-377.
16. Grundfest, C.C., Chang, J., and Newcombe, D.S. (1982) *Biochem. Biophys. Acta* 713,149-159.
17. Lowry, D.H., Rosenbrough, N.J., Farr, A.L., and Randall, R.J. (1951) *J. Biol. Chem.* 193,265-275.
18. Protection Against Trichothecene Mycotoxins, p. 92-157. (1983) Response in Biological System, National Academy Press, Washington, D.C.
19. Rosenstein, Y., Frayssinet, C.L., Lespinats, G., Losillier, F., Lafont, P., and Frayssinet, C. (1979) *Immunology*, 36, 111-117.
20. Russo-Marie, F., Paing, M., and Duval, D. (1979) *J. Biol. Chem.* 254,8498-8504.
21. Peter-Goldman, M., Bathon, J., Flores, R., Hirata, F., and Newcombe, D. (1984) *Am. Rev. Resp. Dis.*, 130, 803-809.



22. Moore, P.K., and Hoult, J.R.S. (1980) *Nature*, 288,269-270.
23. Beauchamp, R.O., Jr., And Jelkovich, D.A., Kligerman, A.D., Morgan, K.T., and Heck, H.D.A. (1985) *Crit. Rev. Toxicol.* 14, 309-380.
24. Dunham, B., Shepro, D., and Hechtman, H.B. (1984) *Inflammation* 8,313-321.
25. Naseem, S.M., and Newcombe, D.S. (1986) *Pharm. Exp. Ther.* 28,283.
26. Samuelson, B. (1983) *Science* 83,568-575.

Fig. 1. Cultured alveolar macrophages were labeled with  $^{14}\text{C}$ -arachidonic acid for 60 min, washed cells were then exposed to 1.0  $\mu\text{M}$  T-2 toxin, saxitoxin, or microcystin-LR for 2 hr. The media were collected, extracted, and subjected to TLC for prostaglandin separation and measurement. Data represent mean  $\pm$  SEM of 3 separate cultures in duplicate.

\* P-value significant at least  $<0.05$  from control by student "t" test.

Values estimated by one-way analysis of variance test indicate T-2 treatment significantly different at  $<0.05$  level in 6-Keto  $\text{F}_{1\alpha}$  production from microcystin-LR and saxitoxin, and arachidonic acid release from saxitoxin. Microcystin-LR treatment stimulated the release of  $\text{PGE}_2$  as compared to T-2 and saxitoxin ( $p < 0.05$ ).

Table 1  
Effect of NEM and A23187 Ionophore on Prostaglandin Release  
by Alveolar Macrophages in Culture

DPM/Plate					
Treatment	6-Keto F1 $\alpha$	PGF $_2\alpha$	PGE $_2$	TxB $_2$	AA
Control	309 $\pm$ 72	449 $\pm$ 49	311 $\pm$ 29	448 $\pm$ 29	2,654 $\pm$ 379
NEM (5 $\mu$ M)	529 $\pm$ 93 (NS)	476 $\pm$ 32 (NS)	490 $\pm$ 23 ( $<$ 0.05)	860 $\pm$ 82 ( $<$ 0.005)	5,158 $\pm$ 579 ( $<$ 0.05)
A23187 (10 $\mu$ M)	872 $\pm$ 42 ( $<$ 0.005)	531 $\pm$ 51 (NS)	614 $\pm$ 68 ( $<$ 0.01)	820 $\pm$ 75 ( $<$ 0.005)	5,029 $\pm$ 427 ( $<$ 0.01)

Alveolar macrophages were incubated with NEM or A23187 for 60 min in 1 ml PBS. Media were collected, extracted and analyzed by TLC. Results represent mean  $\pm$  SEM of 3 separate experiments in duplicate.

Table 2  
Effect of T-2 Toxin and Fluocinolone on Arachidonic Acid  
and its Metabolite Release in Alveolar Macrophages

DPM/mg Protein				
Treatment		6-Keto F <sub>1α</sub>	TxB <sub>2</sub>	AA
Control	(4)	437 ± 48	544 ± 69	2,879 ± 432
0.1 μM T-2	(3)	554 ± 64 (NS)	768 ± 82 (<0.05)	6,590 ± 978 (<0.01)
1.0 μM T-2	(3)	683 ± 51 (<0.025)	942 ± 61 (<0.01)	6,874 ± 1,124 (<0.01)
1.0 μM T-2 +	(3)			
1.0μM Fluocinolone		523 ± 44 (NS)	580 ± 61* (NS)	4,592 ± 457 (<0.01)

Macrophages were incubated as described in "Materials and Methods."  
1.0μM fluocinolone itself had no effect on release of arachidonic acid or its metabolites. Results represents mean ± SEM of number of experiments in duplicate indicated in the table.

\*P-Value significantly different (<0.05) from 1.0 μM T-2 toxin-treated cultures.

